Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

This study provides ex vivo proof-of-principle that low-intensity ultrasound may protect human hair follicles from paclitaxel-induced damage, potentially reducing chemotherapy-related alopecia.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This paper highlights a case where a 2-year-old boy with temporal triangular alopecia was initially misdiagnosed with alopecia areata, emphasizing the importance of dermoscopy for accurate early diagnosis to avoid unnecessary treatments.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

In this study, MitoQ was found to enhance hair growth and reverse DHT-induced hair loss in a mouse model of androgenetic alopecia by mediating the WNT/β-catenin pathway and increasing CYP19A1 expression, suggesting potential as a therapeutic intervention.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

This study introduces a new multimodal imaging technology to visualize and quantify cell dynamics in natural skin over long durations, demonstrated in GFP bone marrow-transplanted mice, to study dynamic skin regeneration.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

This article reviews approved treatments for androgenetic alopecia and reports no new research findings, highlighting the need for further studies.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study found that in male patients with androgenetic alopecia, combining botulinum toxin type A with 5% Minoxidil significantly improved hair growth, patient satisfaction, and quality of life over six months, compared to using Minoxidil alone, without causing adverse effects.

This review discusses the potential benefits of myo-inositol supplementation for insulin resistance-related disorders and diabetic complications, but reports no new clinical results.

This study found that human TMEM2 does not function as a hyaluronidase but is involved in regulating hyaluronan metabolism.

This study explored the use of an AI-driven device, HairMetrix, to quantitatively assess the effects of PRP treatments on scalp health in two Caucasian women with androgenetic alopecia, reporting increases in average hair width and follicle count after one treatment.

This study demonstrated the potential of a methodology combining ToF-SIMS and AFM to effectively analyze human hair structure and identify cosmetic residues, which can aid the cosmetic industry in product development.

The researchers reported that topical tofacitinib in mice increased hair follicles in the growth phase and boosted noggin and BMP4 mRNA expressions, compared to a vehicle and minoxidil.

This study concluded that adding Kanglaite injection to gemcitabine and cisplatin chemotherapy for advanced non-small cell lung cancer improved response rates and reduced adverse side effects.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

This study investigated how the antioxidant MitoQ and the enzyme CYP19A1 influence mitochondrial function in androgenetic alopecia. In a mouse model, both CYP19A1 overexpression and MitoQ treatment improved mitochondrial health and reversed DHT-induced hair loss factors, suggesting potential therapeutic targets for this condition.

Isoquercitrin helps hair grow by activating certain cell processes.

This study observed that both intralesional triamcinolone acetonide and microneedling with triamcinolone acetonide significantly reduced alopecia areata severity, with no significant difference in effectiveness between the two treatments, suggesting microneedling as an effective and less invasive option.

This study found that microneedles containing magnetic intracellular vesicles and tremella polysaccharide improved the hair microenvironment and accelerated hair regeneration in mice with androgenic alopecia.

In this study, dermatophytosis was prevalent among 52% of dogs and 70% of cats with skin lesions, with younger animals facing higher infection risks; combined itraconazole, clotrimazole, supportive care, and vaccination led to the fastest recovery.

This study developed an algorithm for predicting the impact of innovations on economic growth and reported its potential to enhance innovation policy decisions.

This meeting summary discusses the ISHR's focus on hair restoration, featuring Julius Caesar's image, but reports no new research findings.